Pfizer Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-20 pm EST			After hours 07:56:17 pm
25.52 ^USD	-0.51%		25.55	+0.12%

Jan. 20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
Jan. 20	Global drugmakers rush to boost US presence as tariff threat looms	RE

Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026

Published on 12/12/2025 at 01:20 pm EST

S&P Capital IQ

PFIZER INC.

-0.51%

Pfizer Inc. announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company?s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026.

Latest news about Pfizer Inc.

Jan. 20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
Jan. 20	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 20	Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant	DJ
Jan. 20	Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc	CI
Jan. 20	Novavax Enters Non-Exclusive Licensing Deal With Pfizer	MT
Jan. 20	Novavax Inc enters license agreement with Pfizer - SEC filing	RE
Jan. 20	Novavax signs licensing agreement with Pfizer for vaccine development	RE
Jan. 20	Novavax enters license agreement with Pfizer for vaccine development	RE
Jan. 20	GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update	DJ
Jan. 20	Shionogi & Co Invests $2.13 Billion to Replace Pfizer as ViiV Healthcare Shareholder	MT
Jan. 20	Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake	RE
Jan. 20	GSK boosts pipeline with USD2.2 billion purchase of RAPT Therapeutics	AN
Jan. 20	GSK Partner Shionogi to Acquire Pfizer's Stake in HIV-Focused ViiV Healthcare for $2.13 Billion	MT
Jan. 20	UK unemployment flat; GSK buys RAPT Therapeutics	AN
Jan. 20	GSK, Shionogi Finalize Deal for Pfizer's Exit from ViiV Healthcare	MT
Jan. 20	GSK, Pfizer, and Shionogi agree on ViiV Healthcare shareholding changes	RE
Jan. 20	Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits	RE
Jan. 20	GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug	RE
Jan. 20	Pfizer Limited Announces Senior Management Personnel Changes	CI
Jan. 20	UK Stocks-Factors to watch on January 20	RE
Jan. 19	Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1 Billion	DJ
Jan. 19	Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer	RE
Jan. 19	AIM Vaccine Co., Ltd. Receives Notice of Approval for Drug Clinical Trials Issued by the National Medical Products Administration	CI
Jan. 17	American CEOs push back on Trump ... mildly	RE
Jan. 16	Pfizer-backed Agomab Therapeutics reveals wider loss in US IPO filing	RE

Chart Pfizer Inc.

Duration

Period

PFE: Dynamic Chart

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.

Employees

81,000

Sector

Pharmaceuticals

Calendar

Jan. 22 - Ex-dividend day

More about the company